<DOC>
	<DOC>NCT00675194</DOC>
	<brief_summary>The purpose of this study is to determine which Arm (capecitabine + irinotecan versus capecitabine + cisplatin) shows higher response rates in the treatment of advanced gastric-oesophagal cancer Furthermore, comparison of progression-free survival, 1-year survival, Quality of Life and safety</brief_summary>
	<brief_title>Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer</brief_title>
	<detailed_description>capecitabine + irinotecan versus capecitabine + cisplatin, as published by Kang et al. (ASCO 2006)</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>gastric or gastricoesophagal junction adenocarcinoma unidimensional measurable disease Karnofsky index &gt;/=60% prior chemo or radiotherapy colorectal diseases brain metastases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>cisplatin</keyword>
	<keyword>capecitabine</keyword>
	<keyword>gastric</keyword>
	<keyword>irinotecan</keyword>
	<keyword>metastatic</keyword>
	<keyword>chemotherapy</keyword>
</DOC>